OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🔴 Outlook Therapeutics is trading 11.81% down in after-hours trading with no clear company-specific announcement identified
Outlook Therapeutics is trading 11.81% down at $0.97 after no clear company-specific announcement was identified for August 12, 2026. - The decline is...
🔴 Outlook Therapeutics is trading 5% down today with no clear catalyst
Outlook Therapeutics is trading 5.22% down at $1.09 after no new company-specific announcement was identified for August 11, 2026. - The July 24 FDA approval...
🟢 Outlook Therapeutics is trading 10.72% up today following July 24 FDA approval of LYTENAVA
Outlook Therapeutics is trading at $1.13, up +10.72%, following the July 24 FDA approval of LYTENAVA for wet AMD. - LYTENAVA became the first FDA-approved...
🟢 Outlook Therapeutics is trading 7.35% up today after July 24 FDA approval of LYTENAVA
Outlook Therapeutics is trading 7.35% up now at $1.09, with the move appearing primarily technical and sentiment-driven following the July 24 FDA approval of...
Outlook Therapeutics Won Its FDA Bet — But Can a Cash-Strapped Biotech With $7.7 Million Actually Launch a Drug?
Shares of Outlook Therapeutics slid 7.6% to $0.90 on Thursday as traders cashed in gains from a volatile post-approval rally, raising a harder question:...
🔴 Outlook Therapeutics is trading 5.6% down today
Outlook Therapeutics is trading at $0.97, down -5.58%, with no new negative company-specific catalyst identified for August 6, 2026. - Outlook Therapeutics...
🟢 Outlook Therapeutics is trading 5.7% up today amid biotech sector rebound
Outlook Therapeutics is trading 5.7% up today at $1.01 as shares rebound alongside a broader lift in the biotechnology sector. • The stock continues to...
🟢 Outlook Therapeutics is trading 5.7% up today as it rebounds amid broader biotech sector strength
Outlook Therapeutics is trading 5.7% up at $0.97 today as it rebounds alongside a strong biotech sector following yesterday’s pullback and its late-July...
🔴 Outlook Therapeutics is trading 7.7% down today as it extends a pullback from its recent FDA-driven rally
Outlook Therapeutics is trading at $0.90 (-7.65%) today as the stock extends a pullback from its late-July surge. • The decline is primarily driven by...
🔴 Outlook Therapeutics is trading 10.2% down today on profit-taking following its FDA-driven rally
Outlook Therapeutics is trading 10.2% down at $0.93 on profit-taking and consolidation following a multi-day rally driven by recent FDA approval news. • The...
🔴 Outlook Therapeutics is trading 5.3% down today on profit-taking after a multi-day post-FDA approval rally
Outlook Therapeutics is trading 5.3% down at $0.98 as the stock enters a period of consolidation following a significant multi-day rebound. • The pullback...
🟢 Outlook Therapeutics is trading 5.5% up today as rebound continues after LYTENAVA FDA approval and insider buying
• Outlook Therapeutics is trading 5.5% up at $1.05 as it extends recovery following the FDA approval of its wet AMD therapy, LYTENAVA. • The stock is building...
🟢 Outlook Therapeutics is trading 19% up today as buyers return following a sharp post-FDA approval selloff
Outlook Therapeutics is trading 19% up at $1.08 as buyers step back in following a sharp post-FDA approval selloff in its wet AMD therapy, LYTENAVA. • The...
🟢 Outlook Therapeutics is trading 5% up today as investors bargain hunt after post-FDA approval selloff
Outlook Therapeutics is trading 5% up at $0.95 as investors step back in following a sharp two-day selloff that followed the FDA approval of its wet AMD...
🔴 Outlook Therapeutics Continues Decline with 16% Drop as Investors Take Profits Following FDA Approval of LYTENAVA
• Outlook Therapeutics received FDA approval for its wet age-related macular degeneration (wet AMD) drug, LYTENAVA, on July 27, 2026. • The stock experienced...
🔴 Outlook Therapeutics is trading 9.9% down today on profit-taking after FDA-driven rally
Outlook Therapeutics is trading 9.9% down today at $0.94 as traders lock in profits following a sharp FDA approval-driven rally in its wet AMD program. • The...
🔴 Outlook Therapeutics is trading 10.4% down today as investors lock in profits following an FDA approval-driven rally
Outlook Therapeutics is trading at $0.95 (-10.42%) in pre-market as investors take profits following a significant rally triggered by FDA approval momentum for...
🔴 Outlook Therapeutics is trading 5.2% down today as investors lock in gains following FDA approval momentum
Outlook Therapeutics is trading 5.2% down at $1.01 in pre-market as investors lock in short-term gains following a sharp rally driven by regulatory...
🟢 Outlook Therapeutics is trading 5.2% up today as it rebounds after-hours following FDA approval momentum
Outlook Therapeutics is trading at $1.12 (5.2% up) in after-hours trading, rebounding modestly from a sharp regular-session decline as investors digest the...
Outlook Therapeutics Finally Gets Its FDA Win — But Can a Cash-Strapped Biotech Turn Approval Into Revenue Before the Money Runs Out?
Shares of Outlook Therapeutics surged 8.2% to $1.52 in pre-market trading Monday, extending a rally that began last week after the FDA granted approval to the...